TAVR vs. SAVR Study of VitaFlow Liberty® for Severe BAV Stenosis

A trial with no phase registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 452 participants.

Also called NCT06597188

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 452 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06597188
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT06597188. Randomized; single masking; primary purpose treatment. Start 2025-09-08 (actual); primary completion 2028-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TAVR vs. SAVR Study of VitaFlow Liberty® for Severe BAV Stenosis
Acronym
PROMIS-BAV
Condition
Aortic Stenosis
Condition
Bicuspid Aortic Valve (BAV)
Intervention (Device)
VitaFlow Liberty
Intervention (Device)
Commercially available surgical bioprosthetic valve
Lead sponsor
Shanghai MicroPort CardioFlow Medtech Co., Ltd. (class: industry)
Collaborator
West China Hospital (class: other)
Collaborator
The First Affiliated Hospital of Anhui Medical University (class: other)
Collaborator
First Affiliated Hospital of Zhejiang University (class: other)
Collaborator
Qilu Hospital of Shandong University (class: other)
Collaborator
People's Hospital of Xinjiang Uygur Autonomous Region (class: other)
Collaborator
Fuzhou University Affiliated Provincial Hospital (class: other)
Collaborator
Yan'an Affiliated Hospital of Kunming Medical University (class: other)

Record details

Record id
cardio:ct-nct06597188
Content hash
921f32df3b7bcefbe6918fe46f599541fe0d409b675c9c918564c6d9a604bc77